Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONGeneric

NAFCILLIN SODIUM

NAFCILLIN SODIUM

Standard Dose
EQ 10GM BASE/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview NAFCILLIN SODIUM is listed in Drugs@FDA under application 206761 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient NAFCILLIN SODIUM Form and strength INJECTABLE;INJECTION - EQ 10GM BASE/VIAL Sponsor FRESENIUS Submission history Latest submission status date: 2020-06-02 00:00:00.

Structured Monograph

Clinical summary

Approval overview NAFCILLIN SODIUM is listed in Drugs@FDA under application 206761 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient NAFCILLIN SODIUM Form and strength INJECTABLE;INJECTION - EQ 10GM BASE/VIAL Sponsor FRESENIUS Submission history Latest submission status date: 2020-06-02 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.